And We Have a $26.4 Billion Winning Trifecta!

THREE PREVIOUS WINNERS* Immunomedics (IMMU) $3 to $87 up 2,800%, a gain of $20.7 billion. Acquired...

Report on Citius Pharma (CTXR): North Shore Research Issues a $10 Price Target, a...

We're Up 181% on Citius Pharma (CTXR), Despite its Being Well Below it's Recent High of $4.30. We Now Have Two $10...

Dicerna (DRNA) up 78% Today. Being Acquired by Novo Nordisk (NVO) for $38.00.

We shoot and we score. Up 1,133% since adding to Watch List @ $3.00. Our second...

And We Have Our First MEME Stock! $2.00 to $29.95.

Tiny U.S. Biotech Jumps 930% as It Picks Up Retail Attention (Bloomberg) Guess we were bound to stumble across...

ABVC BioPharma (ABVC) Approved for ABV-1505 Phase II Part II in Taiwan Sites

Gentleman, Start Your Engines? ABVC BioPharma Receives Taiwan Regulatory Approval for ABV-1505 ADHD Phase II Part 2 Clinical Study
Biotech Stock Review

Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.

Added to Watch List November 2019 @$0.55. Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021...
Biotech Stock Review, DYAI

Dyadic (DYAI) Scores $10M deal with Sorrento Therapeutics (SNRE).

Share Price up 27% ($4.63 up $1.04) as Wall Street Sorts out the Terms of the Deal. We've had...

Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.

Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022. CITIUS NEWS ARCHIVE
@bryteeyes3

Citius (CTXR). Dang Flippers!

Short term investors powered Citius from $2.50 to near $4.50 in hopes of a positive early trial...
@NCI

Citius (CTXR) Expands Scientific Advisory Board. Dr. John Laffey, Expert in Stem Cell and...

- Addition of leading scholar and KOL in acute respiratory distress syndrome (ARDS) to ARDS Scientific Advisory Board supports continued progress of...

Latest article

Nine Page Summary Report on GeoVax (GOVX)

This is a great long-term story. We’re telling you. (March 2024) When we finished writing our earlier...

GeoVax (GOVX) Provides First Half 2024 Business Update.

Award of BARDA Project NextGen contract represents a significant milestone event; Total value...

Reverse Split Mania! Solgenix (SNGX) Jumps 448% After 1:16.

Can You Imagine Selling Solgenix at $2.00 yesterday. And to be honest, news wasn't all that big - such...